BD shares fall by 3% after lowering FY26 profit outlook

Becton Dickinson and Company (BD) has trimmed its fiscal year 2026 (FY26) profit outlook to account for the spin-off of its biosciences & diagnostic solutions business, prompting its share price to fall by 3%. BD reached a $17.5bn agreement to merge the unit with Waters, a laboratory equipment maker, in July 2025 and announced the deal’s formal completion alongside its Q1 2026 financials, released ahead of market open on 9 February. Due to the completed transaction with Waters, BD said it now expects FY ...